Valeant Pharmaceuticals

Psoriasis drug approved with boxed warningA new drug to treat moderate-to-severe plaque psoriasis carries a black box warning that suicidal ideas and behavior, including completed suicides, have occurred in patients during the drug’s clinical trials.
B + L dedicated to eye care with strong portfolio, new programsBausch + Lomb (B + L) outlines the company's commitment to eye care with a strong portfolio, new programs, patient access, and better pricing.
Valeant offers discounts on heart drugs
Valeant offers discounts on heart drugsAfter heavy criticism by Congress, presidential candidates and others, Valeant Pharmaceuticals is offering a discount program on its heart drugs Nitropress and Isuprel.
Valeant responds to drug price concerns with cutsValeant Pharmaceuticals just entered into a new fulfillment agreement with Walgreens and says it will reduce prices of its branded prescription-based dermatological and ophthalmological products such as Jublia by 10 percent.
Valeant CEO says drug pricing may dropThe CEO of Valeant Pharmaceuticals, which is being investigated by the government for raising drug prices, predicted more modest price increases ahead for the pharmaceutical industry.
U.S. prosecutors investigating Valeant PharmaceuticalsCanadian drug maker Valeant Pharmaceuticals recently acknowledged that U.S. prosecutors have subpoenaed documents on its drug pricing.
Update: Actavis and Allergan leaders discuss merger dealActavis CEO Brent Saunders and Allergan CEO David Pyott discuss the recent acquisition deal between the two companies with industry media.
Actavis-Allergan deal seen as ‘marriage of 2 great companies’
Actavis-Allergan deal seen as ‘marriage of 2 great companies’In November, Actavis announced it was acquiring Allergan in a $66 billion acquisition, thus thwarting a 7-month effort by Valeant Pharmaceuticals.
Valeant acquires Nicox Inc.Nicox S.A. announced that Valeant Pharmaceuticals has acquired Nicox’s U.S. diagnostics subsidiary Nicox Inc., in a deal worth up to $20 million.
Judge: Yes to Allergan shareholder meeting, but questions Valeant, Pershing Square joint bidA U.S. district court has ruled that Pershing Square Capital Management can vote its 9.7% stake in Allergan in a special shareholder meeting on Dec. 18.